J Korean Diabetes.  2017 Sep;18(3):155-159. 10.4093/jkd.2017.18.3.155.

Diabetes and Endocrine Disease

• Bae JC
• Han JM

• KMID: 2390868
• DOI: http://doi.org/10.4093/jkd.2017.18.3.155

Abstract

Impaired insulin secretion and insulin resistance are the two main mechanisms leading to type 2 diabetes mellitus. Insulin exerts multiple effects upon target cells, especially skeletal muscle, liver, and adipose tissue. In general, insulin promotes storage of glucose and inhibits the breakdown of stored glycogen into glucose. The counter regulatory hormones glucagon, catecholamine, cortisol and growth hormone are released during hypoglycemia and under other stress conditions. These hormones have insulin-antagonistic effects both in the liver and in the peripheral tissues. A significant number of endocrine disorders is associated with varying degrees of glucose intolerance, with which sustained excess of these hormones is associated. Indeed, type 2 diabetes is frequently observed in patients with various hormonal diseases including acromegaly, Cushing syndrome, pheochromocytoma, hyperthyroidism, and glucagonoma. In particular, improvement of glycemic control following treatment for these hormonal diseases confirms a causal relationship between excess of these hormones and diabetes. In this review, there will be a discussion over these endocrine diseases in relation to diabetes.

Keyword

Acromegaly; Cushing syndrome; Diabetes mellitus; Hyperthyroidism

MeSH Terms

Acromegaly
Adipose Tissue
Cushing Syndrome
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases*
Glucagon
Glucagonoma
Glucose
Glucose Intolerance
Glycogen
Growth Hormone
Humans
Hydrocortisone
Hyperthyroidism
Hypoglycemia
Insulin
Insulin Resistance
Liver
Muscle, Skeletal
Pheochromocytoma
Glucagon
Glucose
Glycogen
Growth Hormone
Hydrocortisone
Insulin

Reference

References

1. Resmini E, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol. 2009; 46:85–95.

2. Park Y. Endocrine diseases in diabetes mellitus. Hanyang Med Rev. 2012; 32:171–8.

3. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000; 106:329–33.

4. Coller FA, Huggins CB. Effect of hyperthyroidism upon diabetes mellitus: striking improvement in diabetes mellitus from thyroidectomy. Ann Surg. 1927; 86:877–84.

5. Wang C. The relationship between type 2 diabetes mellitus and related thyroid diseases. J Diabetes Res. 2013; 2013:390534.

6. Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes mellitus. J Thyroid Res. 2011; 2011:439463.

7. Weinstein SP, O'Boyle E, Fisher M, Haber RS. Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. Endocrinology. 1994; 135:649–54.

8. Haluzik M, Nedvidkova J, Bartak V, Dostalova I, Vlcek P, Racek P, Taus M, Svacina S, Alesci S, Pacak K. Effects of hypo- and hyperthyroidism on noradrenergic activity and glycerol concentrations in human subcutaneous abdominal adipose tissue assessed with microdialysis. J Clin Endocrinol Metab. 2003; 88:5605–8.

9. Vaughan M. An in vitro effect of triiodothyronine on rat adipose tissue. J Clin Invest. 1967; 46:1482–91.

10. Lambadiari V, Mitrou P, Maratou E, Raptis AE, Tountas N, Raptis SA, Dimitriadis G. Thyroid hormones are positively associated with insulin resistance early in the development of type 2 diabetes. Endocrine. 2011; 39:28–32.

11. O'Meara NM, Blackman JD, Sturis J, Polonsky KS. Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism. J Clin Endocrinol Metab. 1993; 76:79–84.

12. Dimitriadis G, Baker B, Marsh H, Mandarino L, Rizza R, Bergman R, Haymond M, Gerich J. Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am J Physiol. 1985; 248:E593–601.

13. Beer SF, Parr JH, Temple RC, Hales CN. The effect of thyroid disease on proinsulin and C-peptide levels. Clin Endocrinol (Oxf). 1989; 30:379–83.

14. Leong KS, Wallymahmed M, Wilding J, MacFarlane I. Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. Postgrad Med J. 1999; 75:467–70.

15. Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, Koukkou E, Tzanela M, Thalassinos N, Raptis SA. Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab. 2006; 91:4930–7.

16. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing's syndrome. Endocrinol Metab Clin North Am. 2008; 37:135–49. ix.

17. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999; 84:2664–72.

18. Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary. 2004; 7:253–6.

19. Meier C, Kapellen T, Tröbs RB, Hirsch W, Parwaresch R, Kiess W, Körholz D. Temporary diabetes mellitus secondary to a primary pancreatic Burkitt lymphoma. Pediatr Blood Cancer. 2006; 47:94–6.

20. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006; 355:2558–73.

21. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-Chazot F, Brue T, Delemer B. French Acromegaly Registry. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 2011; 164:877–84.

22. Yoo SJ. Diagnosis and treatment of pheochromocytoma. Korean J Med. 2012; 82:403–10.

23. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens. 2003; 21:1703–7.